In a Phase I/II trial, patients with X-linked chronic granulomatous disease will receive a treatment created using a new ...
The company expects to submit a biologics license application for NTLA-2002 in 2026 and potentially launch it in the US in 2027.
The drug was previously available through the Cancer Drugs Fund, but with more data, NICE is backing routine access through the NHS.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback